Top Markets
#1 Doge Strategy Doge Strategy +953,314.18%
#2 Noon Noon +12,208.80%
#3 Siren Siren +112.06%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +46.63%
#6 Gigachad Gigachad +28.15%
#7 Ontology Ontology +20.38%
#8 Scor Scor +18.84%
#9 Win Win +17.98%
#10 TRIA TRIA +17.79%
Coin of the day
Doge Strategy Doge Strategy
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang în acțiuni #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Preț acțiune
$0.0416118
Capitalizare de piață
$12.78M
Schimbare (1 zi)
1.72%
Schimbare (1 an)
-22.01%
Țară
AU
Tranzacționează Noxopharm Limited (NOX)

Categorie

Healthcare
Marja operațională pentru Noxopharm Limited (NOX)
Marja operațională la March 2026 TTM: -532.32%
Conform celor mai recente rapoarte financiare și prețului acțiunilor Noxopharm Limited, marja operațională curentă (TTM) este -532.32%. La finalul anului 2024, compania avea o marjă operațională de -313.92%.
Istoricul marjei operaționale pentru Noxopharm Limited din 2016 până în 2026
Marja operațională la sfârșitul fiecărui an
An Marja Operațională Schimbă
2026 (TTM) -532.32% 55.59%
2025 -342.14% 8.99%
2024 -313.92% 13.69%
2023 -276.12% -1.43%
2022 -280.14% 7.54%
2021 -260.50% 31.83%
2020 -197.61% -52.69%
2019 -417.69% -63.54%
2018 -1,145.69% -55.34%
2017 -2,565.11% 0.00%
2016 0.00% 0.00%
Marja operațională pentru companii similare sau concurente
Companie Marja Operațională Diferență în marja operațională Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.08%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.07%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.05%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.05%
AU
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.